Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.

Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N.

Front Oncol. 2019 Sep 10;9:832. doi: 10.3389/fonc.2019.00832. eCollection 2019.

2.

Hopes and failures in front-line ovarian cancer therapy.

Tsibulak I, Zeimet AG, Marth C.

Crit Rev Oncol Hematol. 2019 Aug 14;143:14-19. doi: 10.1016/j.critrevonc.2019.08.002. [Epub ahead of print] Review.

3.

Clinical Impact of RANK Signalling in Ovarian Cancer.

Wieser V, Sprung S, Tsibulak I, Haybaeck J, Hackl H, Fiegl H, Marth C, Zeimet AG.

Cancers (Basel). 2019 Jun 8;11(6). pii: E791. doi: 10.3390/cancers11060791.

4.

Ovarian Cancer Stem Cell Heterogeneity.

Hatina J, Boesch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet AG.

Adv Exp Med Biol. 2019;1139:201-221. doi: 10.1007/978-3-030-14366-4_12. Review.

PMID:
31134503
5.

NADPH oxidase 4 expression in the normal endometrium and in endometrial cancer.

Degasper C, Brunner A, Sampson N, Tsibulak I, Wieser V, Welponer H, Marth C, Fiegl H, Zeimet AG.

Tumour Biol. 2019 Feb;41(2):1010428319830002. doi: 10.1177/1010428319830002.

PMID:
30813866
6.

Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer.

Wieser V, Tsibulak I, Degasper C, Welponer H, Leitner K, Parson W, Zeimet AG, Marth C, Fiegl H.

Cancer Sci. 2019 Mar;110(3):1117-1126. doi: 10.1111/cas.13955. Epub 2019 Feb 16.

7.

Immunotherapy in ovarian cancer: fake news or the real deal?

Marth C, Wieser V, Tsibulak I, Zeimet AG.

Int J Gynecol Cancer. 2019 Jan;29(1):201-211. doi: 10.1136/ijgc-2018-000011. Review.

PMID:
30640705
8.

Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.

Schirmer U, Fiegl H, Pfeifer M, Zeimet AG, Müller-Holzner E, Bode PK, Tischler V, Altevogt P.

BMC Cancer. 2018 Oct 29;18(1):1047. doi: 10.1186/s12885-018-4928-y.

9.

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.

Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.

Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.

10.

Evaluation of Vav3.1 as prognostic marker in endometrial cancer.

Boesch M, Sopper S, Marth C, Fiegl H, Wiedemair A, Rössler J, Hatina J, Wolf D, Reimer D, Zeimet AG.

J Cancer Res Clin Oncol. 2018 Oct;144(10):2067-2076. doi: 10.1007/s00432-018-2725-2. Epub 2018 Aug 6.

11.

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.

Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Zeimet AG, Fiegl H, Marth C.

Oncotarget. 2018 Apr 3;9(25):17501-17511. doi: 10.18632/oncotarget.24770. eCollection 2018 Apr 3.

12.

(Iso-)form Matters: Differential Implication of Vav3 Variants in Ovarian Cancer.

Boesch M, Reimer D, Sopper S, Wolf D, Zeimet AG.

Oncologist. 2018 Jul;23(7):757-759. doi: 10.1634/theoncologist.2017-0683. Epub 2018 Apr 19. No abstract available.

13.

Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.

Oskay-Özcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC, Cormio G, Joly F, Kurtz JE, du Bois A, Maciejewski M, Jedryka M, Vergote I, Van Nieuwenhuysen E, Casado A, Mendiola C, Achimas-Cadariu P, Vlad C, Reimer D, Zeimet AG, Friedlander M, Sehouli J.

Ann Oncol. 2018 Apr 1;29(4):910-916. doi: 10.1093/annonc/mdy037.

PMID:
29415128
14.

Front-line therapy of advanced epithelial ovarian cancer: standard treatment.

Marth C, Reimer D, Zeimet AG.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii36-viii39. doi: 10.1093/annonc/mdx450. Review.

PMID:
29232473
15.

Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.

Reimer D, Boesch M, Wolf D, Marth C, Sopper S, Hatina J, Altevogt P, Parson W, Hackl H, Zeimet AG.

Int J Cancer. 2018 Apr 15;142(8):1640-1651. doi: 10.1002/ijc.31186. Epub 2017 Dec 14.

16.

AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS).

Zeimet AG, Mori H, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer C, Wimmer K, Zschocke J, Marth C.

Arch Gynecol Obstet. 2017 Jul;296(1):123-127. doi: 10.1007/s00404-017-4392-y. Epub 2017 May 16.

17.

L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer.

Abdel Azim S, Sprung S, Mutz-Dehbalaie I, Fessler S, Zeimet AG, Marth C.

Int J Gynecol Pathol. 2017 Jul;36(4):356-363. doi: 10.1097/PGP.0000000000000338.

PMID:
28221216
18.

L1CAM in the Early Enteric and Urogenital System.

Pechriggl EJ, Concin N, Blumer MJ, Bitsche M, Zwierzina M, Dudas J, Koziel K, Altevogt P, Zeimet AG, Fritsch H.

J Histochem Cytochem. 2017 Jan;65(1):21-32. doi: 10.1369/0022155416677241. Epub 2016 Nov 12.

19.

Evaluating L1CAM expression in human endometrial cancer using qRT-PCR.

Notaro S, Reimer D, Duggan-Peer M, Fiegl H, Wiedermair A, Rössler J, Altevogt P, Marth C, Zeimet AG.

Oncotarget. 2016 Jun 28;7(26):40221-40232. doi: 10.18632/oncotarget.9574.

20.

Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche.

Boesch M, Sopper S, Zeimet AG, Reimer D, Gastl G, Ludewig B, Wolf D.

Biochim Biophys Acta. 2016 Dec;1866(2):276-289. doi: 10.1016/j.bbcan.2016.10.003. Epub 2016 Oct 15. Review.

21.

Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.

Notaro S, Reimer D, Fiegl H, Schmid G, Wiedemair A, Rössler J, Marth C, Zeimet AG.

BMC Cancer. 2016 Aug 2;16:589. doi: 10.1186/s12885-016-2637-y.

22.

Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO).

Volgger BM, Windbichler GH, Zeimet AG, Graf AH, Bogner G, Angleitner-Boubenizek L, Rohde M, Denison U, Sliutz G, Fuith LC, Fuchs D, Marth C.

Ann Oncol. 2016 Sep;27(9):1740-6. doi: 10.1093/annonc/mdw248. Epub 2016 Jun 29.

PMID:
27358381
23.

High prevalence of side population in human cancer cell lines.

Boesch M, Zeimet AG, Fiegl H, Wolf B, Huber J, Klocker H, Gastl G, Sopper S, Wolf D.

Oncoscience. 2016 Apr 10;3(3-4):85-87. doi: 10.18632/oncoscience.300. eCollection 2016.

24.

Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer.

Abdel Azim S, Duggan-Peer M, Sprung S, Reimer D, Fiegl H, Soleiman A, Marth C, Zeimet AG.

Oncotarget. 2016 Jun 14;7(24):37205-37214. doi: 10.18632/oncotarget.9291.

25.

Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.

Schmid G, Notaro S, Reimer D, Abdel-Azim S, Duggan-Peer M, Holly J, Fiegl H, Rössler J, Wiedemair A, Concin N, Altevogt P, Marth C, Zeimet AG.

BMC Cancer. 2016 Feb 15;16:102. doi: 10.1186/s12885-016-2135-2.

26.

Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.

Petru E, Singer CF, Polterauer S, Galid A, Schauer C, Klocker J, Seifert M, Reinthaller A, Benedicic C, Hubalek M, Hefler L, Marth C, Scholl-Firon T, Bogner G, Zeimet AG.

Wien Med Wochenschr. 2015 Oct;165(19-20):387-94. doi: 10.1007/s10354-015-0392-3. Epub 2015 Oct 15. Review.

PMID:
26471371
27.

Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.

Boesch M, Zeimet AG, Rumpold H, Gastl G, Sopper S, Wolf D.

Stem Cells Transl Med. 2015 Sep;4(9):1028-32. doi: 10.5966/sctm.2015-0054. Epub 2015 Jul 1.

28.

AGO Austria recommendations for genetic testing of patients with ovarian cancer.

Marth C, Hubalek M, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer CF, Zschocke J, Zeimet AG.

Wien Klin Wochenschr. 2015 Aug;127(15-16):652-4. doi: 10.1007/s00508-015-0814-7.

29.

Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.

Volgger B, Zeimet AG, Reinthaller A, Petru E, Schauer C, Klein M, Sevelda-Schwarzgruber U, Bogner G, Wolfram G, Marth C.

Int J Gynecol Cancer. 2015 Feb;25(2):257-62. doi: 10.1097/IGC.0000000000000352.

PMID:
25611899
30.

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell'Anna T, Cretin J, Havsteen H, Bessette P, Zeimet AG, Vergote I, Vasey P, Pujade-Lauraine E, Gladieff L, Ferrero A.

Eur J Cancer. 2015 Feb;51(3):352-8. doi: 10.1016/j.ejca.2014.11.017. Epub 2014 Dec 17.

PMID:
25534295
31.

L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.

Doberstein K, Milde-Langosch K, Bretz NP, Schirmer U, Harari A, Witzel I, Ben-Arie A, Hubalek M, Müller-Holzner E, Reinold S, Zeimet AG, Altevogt P, Fogel M.

BMC Cancer. 2014 Dec 15;14:958. doi: 10.1186/1471-2407-14-958.

32.

The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics.

Boesch M, Zeimet AG, Reimer D, Schmidt S, Gastl G, Parson W, Spoeck F, Hatina J, Wolf D, Sopper S.

Oncotarget. 2014 Aug 30;5(16):7027-39.

33.

miR-21-3p is a positive regulator of L1CAM in several human carcinomas.

Doberstein K, Bretz NP, Schirmer U, Fiegl H, Blaheta R, Breunig C, Müller-Holzner E, Reimer D, Zeimet AG, Altevogt P.

Cancer Lett. 2014 Nov 28;354(2):455-66. doi: 10.1016/j.canlet.2014.08.020. Epub 2014 Aug 19.

PMID:
25149066
34.

Getting the whole picture: adding patient-reported outcomes to adjuvant endocrine treatment evaluation in premenopausal breast cancer patients.

Oberguggenberger A, Goebel G, Beer B, Oberacher H, Meraner V, Sztankay M, Sperner-Unterweger B, Zeimet AG, Marth C, Hubalek M, Holzner B.

Breast J. 2014 Sep-Oct;20(5):555-7. doi: 10.1111/tbj.12323. Epub 2014 Jul 8. No abstract available.

PMID:
25040193
35.

Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.

Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P.

Oncotarget. 2014 Jan 30;5(2):462-72.

36.

Interactions of human peritoneal mesothelial cells with serous ovarian cancer cell spheroids--evidence for a mechanical and paracrine barrier function of the peritoneal mesothelium.

Stadlmann S, Feichtinger H, Mikuz G, Marth C, Zeimet AG, Herold M, Knabbe C, Offner FA.

Int J Gynecol Cancer. 2014 Feb;24(2):192-200. doi: 10.1097/IGC.0000000000000036.

PMID:
24407573
37.

Endometroid carcinoma developing in endometriosis over the symphysis pubis.

Peer M, Fellner W, Seeber BE, Zeimet AG, Marth C.

Gynecol Oncol Case Rep. 2013 Sep 10;6:45-6. doi: 10.1016/j.gynor.2013.08.001. eCollection 2013.

38.

A standardized staining protocol for L1CAM on formalin-fixed, paraffin-embedded tissues using automated platforms.

Fogel M, Harari A, Müller-Holzner E, Zeimet AG, Moldenhauer G, Altevogt P.

Int J Biol Markers. 2014 Jun 25;29(2):e180-3. doi: 10.5301/jbm.5000055.

PMID:
24242293
39.

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.

Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I.

Gynecol Oncol. 2013 Oct;131(1):15-20. doi: 10.1016/j.ygyno.2013.07.086. Epub 2013 Jul 20.

PMID:
23877013
40.

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.

Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.

J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50. doi: 10.1093/jnci/djt144. Epub 2013 Jun 18. Erratum in: J Natl Cancer Inst. 2013 Nov 20;105(22):1763.

PMID:
23781004
41.

Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.

Schirmer U, Fiegl H, Pfeifer M, Zeimet AG, Müller-Holzner E, Bode PK, Tischler V, Altevogt P.

BMC Cancer. 2013 Mar 26;13:156. doi: 10.1186/1471-2407-13-156. Erratum in: BMC Cancer. 2018 Oct 29;18(1):1047.

42.

Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium.

Melmer A, Fineder L, Lamina C, Kollerits B, Dieplinger B, Braicu I, Sehouli J, Cadron I, Vergote I, Mahner S, Zeimet AG, Castillo-Tong DC, Ebenbichler CF, Zeillinger R, Dieplinger H.

Gynecol Oncol. 2013 Jan;128(1):38-43. doi: 10.1016/j.ygyno.2012.09.032. Epub 2012 Oct 9.

PMID:
23063758
43.

Ovarian cancer stem cells.

Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, Hofstetter G, Muller-Holzner E, Fiegl H, Marth C, Wolf D, Pesta M, Hatina J.

Neoplasma. 2012;59(6):747-55. doi: 10.4149/neo_2012_094. Review.

PMID:
22862176
44.

Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer.

Petru E, Zeimet AG, Sevelda P, Seifert M, Singer C, Hubalek M, Angleitner-Boubenizek L, Speiser P, Benedicic C, Stummvoll W, Reinthaller A; Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO).

Wien Klin Wochenschr. 2012 Jun;124(11-12):412-8. doi: 10.1007/s00508-012-0185-2. Epub 2012 Jun 28. Erratum in: Wien Klin Wochenschr. 2012 Sep;124(17-18):669. Singer, Christian [added].

PMID:
22739650
45.

Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference.

Hubalek M, Bartsch R, Gnant M, Kapp KS, Lang A, Lax S, Lukas P, Neunteufel W, Pristauz G, Reitsamer R, Sandbichler P, Schrenk P, Singer C, Tamussino K, Tschmelitsch J, Zeimet AG, Marth C.

Geburtshilfe Frauenheilkd. 2012 Apr;72(4):293-298.

46.

DyeCycle Violet used for side population detection is a substrate of P-glycoprotein.

Boesch M, Reimer D, Rumpold H, Zeimet AG, Sopper S, Wolf D.

Cytometry A. 2012 Jun;81(6):517-22. doi: 10.1002/cyto.a.22038. Epub 2012 Mar 7.

47.

Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy.

Meraner V, Gamper EM, Grahmann A, Giesinger JM, Wiesbauer P, Sztankay M, Zeimet AG, Sperner-Unterweger B, Holzner B.

BMC Cancer. 2012 Feb 28;12:77. doi: 10.1186/1471-2407-12-77.

48.

Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer.

du Bois A, Marth C, Pfisterer J, Harter P, Hilpert F, Zeimet AG, Sehouli J.

Int J Gynecol Cancer. 2012 Feb;22(2):182-5. doi: 10.1097/IGC.0b013e31821d419a.

PMID:
22274314
49.

The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer.

Hofstetter G, Berger A, Berger R, Zorić A, Braicu EI, Reimer D, Fiegl H, Marth C, Zeimet AG, Ulmer H, Moll U, Zeillinger R, Concin N.

Int J Gynecol Cancer. 2012 Mar;22(3):372-9. doi: 10.1097/IGC.0b013e31823ca031.

PMID:
22246403
50.

Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation.

Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M, Altevogt P.

Ann Oncol. 2012 Jul;23(7):1795-802. doi: 10.1093/annonc/mdr568. Epub 2012 Jan 6.

PMID:
22228447

Supplemental Content

Loading ...
Support Center